Market Overview

The Global Angina Pectoris Drugs Market was valued at USD 14,485.2 million in 2023 and is expected to reach USD 19,977.0 million by 2031 while growing at a CAGR of 4.1% during the forecast period (2024-2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Market Dynamics

This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global angina pectoris drugs market growth. Angina pectoris drugs, utilized for both symptom management and addressing underlying causes, target the chest pain or discomfort arising from diminished blood flow to the heart muscle. Their objectives encompass relieving chest pain, minimizing angina episodes, and mitigating risks like heart attacks.

Advances in drug development technologies and treatment modalities, coupled with the rising prevalence of angina pectoris, propel market growth, while stringent regulatory requirements and healthcare cost containment measures impede its expansion.

Furthermore, the global angina pectoris drugs industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.

Segmentation – By Therapeutic Class Analysis

The Global Angina Pectoris Drugs Market is segmented among Beta Blockers, Calcium Antagonists, Anticoagulants, Anti-Platelets, and Others, based on Therapeutic Class. In 2023, Beta Blockers accounted for the majority of the market share*.

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Global Angina Pectoris Drugs Market: Regional Analysis

Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Competitive Landscape

Some of the key players operating in the market are Sanofi, Glilead Sciences, AstraZeneca, Amgen, GlaxoSmithKline (GSK), and Eli Lily.

Pfizer

Table of Contents:

1. Research Methodology and Market Scope

• Research Methodology

• Market Scope

2. Executive Summary

3. Global Angina Pectoris Drugs Market Dynamics

• Drivers

• Restraints

• Opportunity

4. Global Angina Pectoris Drugs Industry Analysis

• PEST Analysis

• Porter's Five Force Analysis

• Recent Deals Analysis

5. Global Angina Pectoris Drugs Market Segmentation, By Therapeutic Class

• Global Angina Pectoris Drugs Market Share Analysis, By Therapeutic Class

• Global Angina Pectoris Drugs Market Growth Analysis, By Therapeutic Class

• Global Angina Pectoris Drugs Market Trends, By Therapeutic Class

o Beta Blockers

o Calcium Antagonists

o Anticoagulants

o Anti-Platelets

o Others

6. Global Angina Pectoris Drugs Market Segmentation, By Region

• Global Angina Pectoris Drugs Market Share Analysis, By Region

• Global Angina Pectoris Drugs Market Growth Analysis, By Region

• Global Angina Pectoris Drugs Market Trends, By Region

o North America

o Europe

o Asia Pacific

o Latin America

o Middle East

o Africa

7. Competitive Landscape

• Sanofi*

o Company Overview

o Financial Performance

o Key Development/Strategies

o SWOT Analysis

• Glilead Sciences

• AstraZeneca

• Amgen

• GlaxoSmithKline (GSK)

• Eli Lily

• Pfizer

*Similar analysis will be provided for each company listed above.